|
BGI, H3 initiate cancer data
partnership
03-22-2013
EDIT CONNECT
SHARING OPTIONS:
CAMBRIDGE, Mass.—Biopharmaceutical company H3 Biomedicine
Inc. and genomics giant BGI have jointly announced the initiation of a
partnership for the
sequencing and publishing of genomic data from preclinical
cancer models. The research will be aimed at identifying and validating
recurrent gene
mutations that could represent potential targets for drug
therapies. Once the analysis is complete, BGI and H3 Biomedicine will publish
the cancer
genomic data and make it available to the global research community.
"We are pleased to collaborate
with H3 Biomedicine, and to
have this opportunity to apply our state-of-the-art, next-gen sequencing
capabilities and bioinformatics expertise to help
advance the discovery of
novel cancer drug targets and full-scale pharmacogenomics findings," Yingrui
Li, CEO of BGI Americas, said in a press release
regarding the agreement. "I
believe this partnership will yield significant, valuable genomic information
that will lay a solid foundation for
developing pre-clinical cancer models and
new anticancer drugs to benefit human health. BGI, in keeping with our global
legacy of collaborative,
published research, including our participation in
ICGC, looks forward to partnering with H3 Biomedicine in developing and sharing
this genomic data
with the international research community."
Per the terms of the partnership, BGI will be
responsible
for sequencing 250 cancer cell lines through the use of next-generation,
whole-exome sequencing in the first study. Once the sequencing is
complete, the
partners will perform a joint analysis of the data to produce a highly curated
set of genetically profiled, preclinical model
information. No financial terms
for the partnership were released.
"We truly believe that genomic
information generated from
patient samples or material derived thereof should be shared with the
scientific community. As a matter of fact, the
community has benefited
enormously from collaborative efforts like The Cancer Genome Atlas and
International Cancer Genome
Consortium," Markus Warmuth, M.D., president and
CEO of H3 Biomedicine, commented in a statement. "Open access to this
information has enabled
countless scientific advances, and our intention is to
further accelerate oncology drug discovery by releasing the data we generate
with BGI. We see
this as a significant step in building shared translational
oncology platforms that will bring the research community together to deliver
new
personalized medicines, especially for those people living with cancers for
which there are, today, limited treatment options."
Both companies are dedicated to making relevant data
available to the public in order to accelerate drug discovery
and development.
H3 Biomedicine announced a similar collaboration in December 2012 with Sage
Bionetworks. Per the strategic collaboration, the two partners agreed to
jointly develop software platforms that would
advance H3 Biomedicine's cancer
genomics research. Both companies agreed to make the data and tools that result
from the agreement accessible to other
organizations involved in cancer
research.
SOURCE: H3 Biomedicine press
release Code: E03211301 Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|